Table 5.
Distribution of patients in the study population according to gastric function assay serologic profile. G-17, gastrin 17; CGA-C, corpus localized chronic atrophic gastritis; F, female; GERD, gastroesophageal reflux disease; Hp, Helicobacter pylori; M, male; PGI, prostaglandin I; PGII prostaglandin II; PPI, proton pump inhibitor.
| Healthy stomach | GERD | Hp infection | Hp eradicated | PPI therapy | CGA-C | |
|---|---|---|---|---|---|---|
| Patients, n. | 94 | 50 | 56 | 30 | 48 | 4 |
| Sex (M/F) | 30/64 | 26/24 | 22/34 | 12/18 | 22/26 | 2/2 |
| Age (yrs) | 36,2±11,3 | 35,8±9,8 | 38,5±10,7 | 50,9±15,8 | 39,3±11,7 | 53,5±22,0 |
| PGI (ug/L) | 81,2±32,0 | 87,7±42,2 | 125,9±64,7 | 122,6±96,1 | 198,0±58,3 | 11,7±7,8 |
| PGII (ug/L) | 6,0±2,4 | 6,9±3,9 | 15,5±10,0 | 10,8±9,8 | 15,6±8,4 | 10.0±8,5 |
| PGI/PGII | 14,0±4,3 | 13,4±4,6 | 8,9±3,4 | 12,2±4,9 | 14,8±6,0 | 1,5±1,3 |
| G-17 (pmol/L) | 3,2±2,7 | 0,7±0,6 | 8,8±8,5 | 9,8±20,1 | 17,5±14,2 | 31,5±28,2 |
| Hp IgG (EIU) | 7,2±6,3 | 5,7±4,1 | 81,8±28,0 | 26,33±12,8 | 9,9±9,1 | 15,7±10,4 |